Crystal Bernstein, MD
Gastroenterology · Seattle, WANPI 1326019167
Payments from drug & device makers
Across 68 payments — averaging $92.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$5K
- AbbVie$421
- Pfizer$366
- Bristol Myers Squibb$268
- Johnson & Johnson$91
- Aimmune Therapeutics, Inc.$57
- plus $182 from 8 others
What the payments were for
- Consulting fees$4,75075%
- Travel & lodging$1833%
- Food & beverage$1,35121%
- Education$331%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 3 | $4,933 |
| AbbVie | 12 | $421 |
| Pfizer | 17 | $366 |
| Bristol Myers Squibb | 21 | $268 |
| Johnson & Johnson | 4 | $91 |
| Aimmune Therapeutics, Inc. | 2 | $57 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $47 |
| Sanofi | 1 | $26 |
| Madrigal Pharmaceuticals | 1 | $25 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Celltrion USA Inc. | 1 | $17 |
| Ferring Pharmaceuticals Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Intercept Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OMVOH$4,750
How this compares
$6,316 in reported general payments places this provider in the 80th percentile of 447 gastroenterology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 182 | $11,882 |
| Budesonide DrBudesonide | 17 | $11,412 |
| Omeprazole | 210 | $3,063 |
| Pantoprazole Sodium | 110 | $1,542 |
| Sucralfate | 19 | $1,519 |
| Rabeprazole Sodium | 18 | $1,469 |
| Famotidine | 70 | $1,332 |
| Esomeprazole Magnesium | 17 | $751 |
| Nortriptyline Hcl | 15 | $274 |
| Dicyclomine Hcl | 32 | $252 |
| Sulfasalazine | 12 | $125 |
| Ondansetron OdtOndansetron | 12 | $90 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Seattle
- Kris KowdleySeattle$5.9M
- Scott LeeSeattle$3.7M
- Timothy ZismanSeattle$3.3M
- James LordSeattle$1.9M
- Charles LandisSeattle$1.7M
- Asma SiddiqueSeattle$1.3M
- Karlee AuskSeattle$758K
- Andrew RossSeattle$687K
- Sravanthi ParasaSeattle$485K
- Lei YuSeattle$407K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.